New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 20, 2014
07:08 EDTNNVCNanoViricides reports construction of new facility nearing completion
NanoViricides reported that construction of the modern R&D Lab and cGMP Clinical Production facility in Shelton, Connecticut, is nearing completion with some weather-related delays. The company reports that the R&D lab section of the facility is ahead of schedule. Once construction of the cGMP Clean Room Production Suite is completed, the project will enter the facility testing and validation phase. The company is performing certain scale-up studies and production of the quantities of FluCide needed for the “Tox Package” study at its current facility, as previously reported. The company anticipates transitioning staff to the new facility upon obtaining a Certificate of Occupancy. The total renovation project went through many changes of design and scope to fit the budget. Construction began in earnest around August 2013, as previously reported by the company. Though generally on schedule, the recent severe winter weather has delayed delivery of certain specialty equipment necessary for the cGMP Clean Room and has created some construction delays.
News For NNVC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 25, 2015
09:14 EDTNNVCNanoViricides provides quarterly report
NanoViricides filed its quarterly report with the SEC estimating that it now has approximately $36.4M of current assets plus restricted cash as of December 31, 2014. The company's operating expenditure during this quarter was approximately $1.9M. Shareholder equity stood at approximately $30.5M for the quarter. The company reported that all of its drug development programs are progressing satisfactorily and that it will continue to provide updates as appropriate. The company's anti-Ebola nanoviricide drug candidates have been sent for testing at a prestigious BSL4 facility in the .S. The company has the ability to produce sufficient quantities of a successful drug candidate for potential field use. The company estimates that the cash in hand is sufficient to enable initial human clinical trials of injectable FluCide drug candidate, as well as possibly to advance another drug candidate towards initial human clinical trials.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use